New cell implant aims to curb severe low blood sugar in type 1 diabetes
NCT ID NCT06651515
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new treatment called SR-02, which involves implanting insulin-producing cells into the abdomen of adults with type 1 diabetes who experience dangerously low blood sugar. Participants would need to take lifelong anti-rejection drugs to prevent the body from attacking the implanted cells. The study was withdrawn before enrolling anyone, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 1 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UPMC Presbyterian Shadyside
Pittsburgh, Pennsylvania, 15213, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States